Search results
Results from the WOW.Com Content Network
docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin), pertuzumab (Perjeta) breast cancer with positive HER2/neu receptor Thal/Dex thalidomide, dexamethasone: multiple myeloma: TIP paclitaxel (Taxol), ifosfamide, platinum agent cisplatin (Platinol) testicular cancer, germ cell tumors in salvage therapy EE-4A: vincristine, actinomycin [8 ...
Pertuzumab is administered as an intravenous infusion in combination with trastuzumab and docetaxel as a first line treatment for HER2-positive metastatic breast cancer. [4] [3] It is also used in the same combination as a neoadjuvant (given to reduce the size of a tumor, prior to surgery or radiation) for HER2-positive early breast cancer; as of 2016 this use had not been shown to increase ...
First line treatment for metastatic breast cancer: the MARIANNE study [33] compares taxane (docetaxel or paclitaxel) plus trastuzumab vs T-DM1 vs T-DM1 plus pertuzumab as first-line treatment for people with HER2 positive unresectable locally advanced or metastatic breast cancer; On 19 December 2014, Roche reported the results of the MARIANNE ...
Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan). [11] [12] It is licensed for the treatment of breast cancer or gastric or gastroesophageal ...
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. [ 30 ] [ 27 ] [ 31 ] [ 32 ] It is specifically used for cancer that is HER2 receptor positive . [ 30 ]
The fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase was approved for medical use in the United States in June 2020. [5] [10]The FDA's approval was based on the results of a non-inferiority study in participants with HER2-positive early breast cancer, which demonstrated the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase had comparable efficacy and ...
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.
In September 2006, NICE recommended paclitaxel should not be used in the adjuvant treatment of early node-positive breast cancer. [ 18 ] It is approved in the United States for the treatment of breast, pancreatic, ovarian, Kaposi's sarcoma and non-small-cell lung cancers.